Coeliac disease vaccine trial underway

Proof-of-concept study will determine if the therapy can prevent the need for a gluten-free diet

An international trial is underway to test a vaccine that will potentially end the need for patients with coeliac disease to adhere to gluten-free diets.

The Australian arm of the phase 2 trial of the peptide-based immunomodulatory vaccine therapy will be conducted in Melbourne, Perth, Adelaide and Brisbane.

The randomised, double-blind, placebo-controlled trial will look at the efficacy of a vaccine called Nexvax2 in adult subjects with confirmed coeliac disease who have been following a gluten-free diet for at least 12 consecutive months.

The study will consist of three periods: a screening for six weeks, a 16-week treatment period, and a four-week post-treatment observational follow-up.

It will assess whether the vaccine can specifically target the immune response to gluten and modify associated symptoms.

“This trial is important